A 1-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily.

Trial Profile

A 1-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2012

At a glance

  • Drugs Saredutant (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2012 Actual patient number (125) added as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from in progress to completed.
    • 26 Jul 2007 Updated from NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top